Akebia Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	225.07	160.18	194.62	292.48	211.65	294.64
Revenue Growth (YoY)	32.49%	-17.70%	-33.46%	38.19%	-28.17%	-12.05%
Cost of Revenue	37.55	26.15	39.76	22.5	81.49	63.96
Gross Profit	187.53	134.03	154.86	269.99	130.16	230.68
Selling, General & Admin	109.07	106.55	100.23	138.6	174.14	154.1
Research & Development	47.5	37.65	63.08	129.99	147.85	218.49
Amortization of Goodwill & Intangibles	9.01	36.04	36.04	36.04	36.04	32.62
Operating Expenses	165.57	180.24	199.35	304.63	358.03	405.2
Operating Income	21.95	-46.21	-44.5	-34.64	-227.88	-174.52
Interest Expense	-26.23	-18.19	-6.03	-15.69	-20.02	-8.92
Interest & Investment Income	-	-	-	-	0.07	-
Other Non Operating Income (Expenses)	-6.81	-0.24	0.89	3.15	2.41	1.86
EBT Excluding Unusual Items	-11.08	-64.63	-49.64	-47.18	-245.42	-181.58
Merger & Restructuring Charges	-	-0.06	-0.18	-15.93	-21.58	-68.24
Gain (Loss) on Sale of Investments	-	-	-	-	0.02	0.05
Asset Writedown	-4.21	-4.21	-1.58	-30.24	-15.05	-135.07
Other Unusual Items	-	-0.52	-0.52	-0.87	-	-
Pretax Income	-15.29	-69.41	-51.93	-94.23	-282.02	-384.84
Income Tax Expense	0.62	-	-	-	-	-
Net Income	-15.91	-69.41	-51.93	-94.23	-282.02	-384.84
Net Income to Common	-15.91	-69.41	-51.93	-94.23	-282.02	-384.84
Shares Outstanding (Basic)	245	211	187	183	166	138
Shares Outstanding (Diluted)	245	211	187	183	166	138
Shares Change (YoY)	20.49%	12.53%	2.56%	10.14%	19.85%	16.95%
EPS (Basic)	-0.06	-0.33	-0.28	-0.52	-1.70	-2.78
EPS (Diluted)	-0.06	-0.33	-0.28	-0.52	-1.70	-2.78
Free Cash Flow	32.17	-40.69	-23.38	-73.27	-253.02	-110.71
Free Cash Flow Per Share	0.13	-0.19	-0.13	-0.40	-1.52	-0.80
Gross Margin	83.32%	83.68%	79.57%	92.31%	61.50%	78.29%
Operating Margin	9.75%	-28.85%	-22.86%	-11.84%	-107.67%	-59.23%
Profit Margin	-7.07%	-43.33%	-26.68%	-32.22%	-133.25%	-130.61%
Free Cash Flow Margin	14.29%	-25.40%	-12.02%	-25.05%	-119.55%	-37.57%
EBITDA	32.25	-8.7	-6.87	3.06	-189.91	-139.83
EBITDA Margin	14.33%	-5.43%	-3.53%	1.04%	-89.73%	-47.46%
D&A For EBITDA	10.29	37.5	37.63	37.7	37.97	34.69
EBIT	21.95	-46.21	-44.5	-34.64	-227.88	-174.52
EBIT Margin	9.75%	-28.85%	-22.86%	-11.84%	-107.67%	-59.23%
Revenue as Reported	225.07	160.18	194.62	292.48	211.65	294.64
Advertising Expenses	-	4.6	1	6.7	8.2	5

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q